What Happens If You Fail a Drug Test at a Pain Clinic?

Failing a drug test at a pain clinic does not automatically mean you will be cut off from treatment and shown the door, though that fear is understandable. What actually happens depends on what the unexpected result is, whether you are given a chance to explain it, and how closely your clinic follows published clinical guidelines. In practice, the range of responses runs from a simple conversation and increased monitoring all the way to tapering and discharge from the practice. The specifics matter a great deal, and so does knowing your options.

The Typical Sequence After an Unexpected Result

Pain clinics use urine drug testing as a routine part of managing patients on opioid therapy. The test might turn up something unexpected in two directions: a substance you were not prescribed shows up (an “unexpected positive”), or a medication you are supposed to be taking does not show up (an “unexpected negative”). Both are treated as red flags, though they trigger different concerns. An unexpected positive for an illicit drug or a non-prescribed opioid raises questions about substance misuse. An unexpected negative for a prescribed medication raises questions about whether you are actually taking what was prescribed, or possibly diverting it.

Clinical guidelines recommend that an unexpected result should first prompt a conversation, not an immediate discharge. Expert recommendations emphasize discussing abnormal results with the patient “in a positive and supportive fashion” and using results to strengthen the relationship rather than punish the patient.¹ In many clinics, the first step is scheduling an appointment to go over the results face to face, asking for an explanation, and determining whether confirmatory testing is warranted.

After that conversation, the clinic may take several paths depending on the explanation and the overall clinical picture:

Increased monitoring: More frequent urine tests, shorter prescription intervals, or additional office visits. A consensus panel recommends testing low-risk patients at least once a year, moderate-risk patients twice a year, and high-risk patients three or more times a year, with unexpected results often prompting a shift to more frequent testing.²
Treatment modification: The provider may adjust the opioid regimen, switch medications, lower doses, or add non-opioid therapies.
Referral: If the results suggest a substance use disorder, you may be referred to an addiction specialist or a combined pain-and-addiction program rather than simply being cut loose.
Discharge from the practice: In the most serious or repeated cases, the clinic may choose to terminate the treatment relationship. This is supposed to follow specific procedures to avoid claims of medical abandonment.

Why the Initial Result Might Be Wrong

Before assuming the worst, it is worth understanding that the standard screening test used in most pain clinics is an immunoassay, which is fast and cheap but far from perfect. These tests work by detecting whether a substance in your urine reacts with an antibody designed to bind a particular drug. The problem is that other substances can trigger the same reaction, producing a false positive. Common culprits include over-the-counter cough medicines containing dextromethorphan, certain antibiotics like fluoroquinolones and rifampin, and even diphenhydramine, the active ingredient in many sleep aids and allergy medications.³

False negatives are equally concerning and arguably more damaging. A patient faithfully taking their prescribed oxycodone may test negative for it on a standard immunoassay because many screening panels are designed to detect morphine-class opioids and do not reliably pick up synthetic or semi-synthetic opioids like oxycodone or fentanyl. Researchers have warned that compliant patients “may have been dismissed from pain management practices secondary to false-negative immunoassay test when looking specifically for prescribed oxycodone.”¹ In one study comparing immunoassay results with confirmatory testing using more advanced methods, about a third of all specimens required confirmation, and the immunoassay produced false-positive results for non-opioid drug use in 44% of flagged cases.⁴

The takeaway here is that a presumptive positive on an immunoassay should always be confirmed with a more precise method, such as liquid chromatography-tandem mass spectrometry, before any clinical decision is made.³ If your clinic is making treatment decisions based solely on the initial screening test without confirmatory testing, that is a significant gap in their process, and you have every reason to request confirmation.

Your Doctor May Have Read the Results Wrong

Even when a confirmatory test is run, the results can be misinterpreted. Drug testing reports from advanced analytical methods are complex, listing metabolites and concentrations that require genuine expertise to read. A study examining how providers handled definitive test results found that only about 55% of results had any documented provider interpretation at all. Of those that were documented, roughly 28% were discordant with the laboratory toxicologist’s interpretation, meaning the treating provider reached a different conclusion than the lab expert reviewing the same data.⁵

This is not a small problem. A provider who misreads a result might conclude you are taking something you are not, or that you have stopped taking something you have not stopped. The downstream consequences of that misread can include unjustified treatment changes, unnecessary referrals, or wrongful discharge. If you receive notice that your test was abnormal and the explanation does not make sense to you, asking to see the full laboratory report and requesting a review by the lab’s medical director or toxicologist is reasonable.

Poppy Seeds and Other Dietary Traps

One of the most frequently cited reasons for an unexpected opiate-positive result is poppy seed consumption, and the concern is not a myth. Poppy seeds contain trace amounts of morphine and codeine, and depending on the quantity consumed and the opiate content of the particular seed batch, these traces can push urine concentrations above the screening cutoff. In a controlled study where participants consumed two 45-gram doses of poppy seeds with known opiate content, over 83% of urine specimens tested positive for morphine at the standard 300 microgram-per-liter cutoff. Even at a higher 2,000 microgram-per-liter cutoff, about a quarter of specimens still came back positive.⁶

The variability across food products makes this especially tricky. In a study examining five different poppy seed food products consumed daily, three produced urine results that stayed negative at every time point, while two produced positive results at every non-baseline time point.⁷ A separate study looking at poppy seeds used in curry found that higher doses could cause urine to exceed the 300 nanogram-per-milliliter threshold, and that water intake after eating significantly influenced results.⁸ If you eat baked goods, bagels, or dishes with poppy seeds, a positive opiate screen is a real possibility, and mentioning this to your clinic before the test is a lot more effective than trying to explain it afterward.

When Your Prescribed Medication Does Not Show Up

An unexpected negative for a medication you are supposed to be taking is sometimes more alarming to the clinic than a surprise positive. From the provider’s perspective, if you are prescribed hydrocodone and it is not in your urine, one possibility is that you are selling or giving away the medication rather than taking it. But there are several legitimate explanations that have nothing to do with diversion.

The most common is simply running out early. A patient who takes medication faster than prescribed during a pain flare and then has none left for the days before the test will produce a negative result. Experts have noted this directly as one of several factors that can cause a legitimate negative.¹ Others include hydration status, which affects the concentration of drugs in your urine. In one study, normalizing urine concentrations for hydration level changed positive rates modestly for pain patients whose hydration was unknown, and dramatically for heavily hydrated subjects.⁹ Drinking large amounts of water before a test can dilute your urine enough that a prescribed drug falls below the detection threshold.

Genetic variability in how your body breaks down opioids also plays a role. An estimated 5% to 10% of white individuals have genetic variants of the CYP2D6 enzyme that slow down the clearance of certain opioids like hydrocodone and codeine, while 1% to 7% carry variants associated with rapid metabolism. The prevalence of these variants differs across populations, with lower rates of poor metabolizers in Asian populations and highly variable rates in African populations.¹⁰ A rapid metabolizer might clear a drug from their system faster than expected, while a poor metabolizer might produce unexpected metabolite patterns. Neither scenario reflects misuse, but both can generate confusing test results.

Cannabis and Evolving Clinic Policies

Cannabis occupies an increasingly complicated space in pain management. In states with legal medical or recreational cannabis, patients may assume that a positive THC result on a pain clinic drug test is not a problem. That assumption is often wrong. Many pain clinics, particularly those affiliated with institutions that receive federal funding, still prohibit cannabis use and treat a positive THC screen the same way they would treat an unexpected positive for cocaine or unprescribed opioids.

The disconnect between state laws and institutional policies is well documented. A systematic review examining clinical recommendations around medical cannabis for chronic pain found that prescribing practices and recommendations varied widely and were influenced by the tension between state and federal legal frameworks, institutional policies, and clinician confidence. Epidemiologic data show that states with legal cannabis tend to see declines in opioid prescribing, but individual clinics within those states may still have strict no-cannabis policies.¹¹ If you use cannabis for any reason, ask your pain clinic about their specific policy before your test. Getting this information beforehand avoids an unpleasant surprise.

What Should Happen Versus What Sometimes Does

There is a real gap between best practices and common practice. Guidelines from multiple professional organizations recommend that urine drug testing be used as a clinical tool, not a gotcha mechanism. An unexpected result should be the start of a conversation about whether the patient needs a different treatment approach, more support, or a referral. The expert consensus is clear that the presence of an illicit or unprescribed drug “must not negate the patient’s complaints of pain” but may suggest a concurrent issue like a substance use disorder that needs to be addressed alongside the pain condition.¹

In practice, though, some clinics do use testing punitively. Experts writing on the topic have acknowledged that urine drug tests in non-cancer pain settings are “sometimes utilized in a punitive manner to ‘catch’ the patient.” When a patient is dismissed after a single unexpected result, without confirmatory testing, without a meaningful conversation, and without a plan for continued care, that crosses from clinical decision-making into something that can harm the patient and expose the provider to legal risk.

Medical Abandonment and Your Rights

Abrupt termination from opioid therapy can be dangerous. Patients who are suddenly cut off may experience withdrawal, a worsening pain crisis, or turn to illicit sources for relief. In a medicolegal case report published in a pain medicine journal, a chronic pain patient who was terminated from opioid therapy after diverting opioids subsequently committed suicide. The case examined allegations of medical abandonment and generated recommendations for how providers should handle treatment termination to minimize harm and legal exposure.¹²

If a pain clinic does decide to end the treatment relationship, accepted standards call for providing reasonable notice, offering to continue prescribing during a transition period, providing referrals to other providers, and tapering medications rather than stopping them abruptly. An expert panel has noted that clinicians risk compromising patient care by “denying appropriate treatment or discharging patients from their practice after inaccurately concluding that they are misusing or diverting opioids owing to a false-positive or false-negative UDM result.”² You have the right to request your medical records, seek a second opinion, and find a new provider. If you feel you were discharged without adequate notice or a taper plan, consulting a patient advocate or a medical malpractice attorney is a reasonable step.

What You Can Do If You Get an Unexpected Result

Your strongest move is to be proactive. Before your appointment, make a complete list of everything you are taking, including over-the-counter medications, supplements, and any foods (like poppy seed products) that might cause interference. If you know you have used a substance outside your treatment agreement, being upfront about it is usually better than waiting for the result. Clinics that follow guidelines are supposed to treat disclosures as a clinical finding, not a moral failing.

If you have already received a failed result, here is what to focus on:

Request confirmatory testing: If the result was based on an immunoassay alone, ask for a confirmatory test using mass spectrometry. This is standard practice, and a clinic that refuses has a weak basis for making treatment decisions on the screening result.
Ask for the full report: You have a right to see the laboratory results, not just a verbal summary from your provider. Review the specific analytes and concentrations listed.
Document your medications: Bring prescription bottles, pharmacy printouts, and receipts for over-the-counter products to your follow-up appointment. Physical evidence carries weight.
Ask about the decision process: If the clinic is changing your treatment, ask what specific finding triggered the change and what guidelines or policies they are following. This conversation should be documented in your chart.

Oral Fluid Testing as an Alternative

Some clinics have started using oral fluid (saliva) testing instead of or alongside urine testing. A clinical study comparing paired oral fluid and urine specimens from 133 chronic pain patients found an overall agreement rate of 85% between the two methods, with a Cohen’s Kappa value indicating substantial agreement. Of the 1,544 paired tests, about 5% of analytes were positive in oral fluid but negative in urine, and about 10% were the reverse. The main exceptions were lower detection rates in oral fluid for hydromorphone, oxymorphone, and benzodiazepines.¹³

Oral fluid testing has some practical advantages for patients. It is harder to adulterate or substitute a saliva sample, which means clinics that use it may place less emphasis on observed collection, a process many patients find intrusive and degrading. On the other hand, if you are prescribed one of the medications that oral fluid testing is less sensitive to, you could face the same false-negative problem described earlier with urine immunoassays, just through a different mechanism.

The Cost Side of Drug Testing

Frequent testing adds up financially, and a failed result that triggers increased monitoring means you will be bearing more of those costs. A study examining drug testing costs for privately insured patients between 2015 and 2019 found that out-of-pocket costs for a first drug test averaged about $10.57 for chronic opioid patients, with deductibles averaging $7.33 and co-insurance around $2.53.¹⁴ Those numbers can climb quickly when you are being tested quarterly or monthly instead of annually, especially if confirmatory testing is added. Patients without insurance or with high-deductible plans feel this more acutely, and the financial burden can become a barrier to staying in compliant care.

Some patients facing repeated testing have found it helpful to contact their insurance company directly to understand what is covered and at what frequency, and to ask the clinic whether presumptive screening alone (less expensive) is being used at routine visits, with confirmatory testing reserved for unexpected results. Knowing the cost structure in advance helps you plan and also gives you a basis for questioning charges that seem disproportionate to the testing performed.

1
ScienceDirect (Journal of Pain and Symptom Management). Urine drug testing in pain medicine
2
Oxford Academic. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations
3
PubMed Central. Toxicologic testing for opiates: understanding false-positive and false-negative test results
4
PubMed. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients
5
PubMed Central. Provider Misinterpretation, Documentation, and Follow-Up of Definitive Urine Drug Testing Results
6
PubMed Central. Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content
7
PubMed. Urine and hair drug test results associated with daily consumption of codeine-predominant poppy seed food products
8
PubMed. Profiling of morphine and codeine in urine after the ingestion of curry containing poppy seed as an evidence for opiates defence in Malaysia
9
Oxford Academic (Journal of Analytical Toxicology). Normalization of Urinary Drug Concentrations with Specific Gravity and Creatinine
10
Mayo Clinic Proceedings. Opioid Metabolism
11
Pain Management Nursing. Clinical Recommendations and Prescriptive Practices of Medical Cannabis for Chronic Pain: A Systematic Review
12
Oxford Academic Pain Medicine. Alleged Medical Abandonment in Chronic Opioid Analgesic Therapy: Case Report
13
Journal of Analytical Toxicology. Oral Fluid Drug Testing of Chronic Pain Patients. II. Comparison of Paired Oral Fluid and Urine Specimens
14
ScienceDirect (Journal of Substance Use and Addiction Treatment). Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015–2019